المؤلفون: G. Leslie Burnett (1530964), Yu C. Yang (14271182), James B. Aggen (1748029), Jennifer Pitzen (1332948), Micah K. Gliedt (14271185), Chris M. Semko (2126905), Abby Marquez (14271188), James W. Evans (1360215), Gang Wang (36685), Walter S. Won (14271191), Aidan C. A. Tomlinson (14271194), Gert Kiss (1345821), Christos Tzitzilonis (275867), Arun P. Thottumkara (2677906), James Cregg (7306595), Kevin T. Mellem (1892248), Jong S. Choi (14271197), Julie C. Lee (2983218), Yongyuan Zhao (14271200), Bianca J. Lee (11216484), Justin G. Meyerowitz (14271203), John E. Knox (2523913), Jingjing Jiang (128923), Zhican Wang (2275534), David Wildes (9434006), Zhengping Wang (1434643), Mallika Singh (202117), Jacqueline A. M. Smith (14271206), Adrian L. Gill (2396434)

مصطلحات موضوعية: Biophysics, Biochemistry, Medicine, Molecular Biology, Pharmacology, Biotechnology, Developmental Biology, Cancer, Infectious Diseases, Chemical Sciences not elsewhere classified, multiple allosteric inhibitors, also preserving selectivity, also present evidence, allosteric binding sites, steric inhibitors ”, mutant cancer drivers, activated tumors hyperactivation, >< sup ><, orthosteric dual inhibitors, development candidate rmc, g12c , g12c <, steric inhibitor, mutant nsclc, many tumors, >, “ bi, selective bi, preclinical profile, preclinical model

Relation: https://figshare.com/articles/journal_contribution/Discovery_of_RMC-5552_a_Selective_Bi-Steric_Inhibitor_of_mTORC1_for_the_Treatment_of_mTORC1-Activated_Tumors/21741425

الاتاحة: https://doi.org/10.1021/acs.jmedchem.2c01658.s001

المؤلفون: G. Leslie Burnett (1530964), Yu C. Yang (14271182), James B. Aggen (1748029), Jennifer Pitzen (1332948), Micah K. Gliedt (14271185), Chris M. Semko (2126905), Abby Marquez (14271188), James W. Evans (1360215), Gang Wang (36685), Walter S. Won (14271191), Aidan C. A. Tomlinson (14271194), Gert Kiss (1345821), Christos Tzitzilonis (275867), Arun P. Thottumkara (2677906), James Cregg (7306595), Kevin T. Mellem (1892248), Jong S. Choi (14271197), Julie C. Lee (2983218), Yongyuan Zhao (14271200), Bianca J. Lee (11216484), Justin G. Meyerowitz (14271203), John E. Knox (2523913), Jingjing Jiang (128923), Zhican Wang (2275534), David Wildes (9434006), Zhengping Wang (1434643), Mallika Singh (202117), Jacqueline A. M. Smith (14271206), Adrian L. Gill (2396434)

مصطلحات موضوعية: Biophysics, Biochemistry, Medicine, Molecular Biology, Pharmacology, Biotechnology, Developmental Biology, Cancer, Infectious Diseases, Chemical Sciences not elsewhere classified, multiple allosteric inhibitors, also preserving selectivity, also present evidence, allosteric binding sites, steric inhibitors ”, mutant cancer drivers, activated tumors hyperactivation, >< sup ><, orthosteric dual inhibitors, development candidate rmc, g12c , g12c <, steric inhibitor, mutant nsclc, many tumors, >, “ bi, selective bi, preclinical profile, preclinical model

Relation: https://figshare.com/articles/dataset/Discovery_of_RMC-5552_a_Selective_Bi-Steric_Inhibitor_of_mTORC1_for_the_Treatment_of_mTORC1-Activated_Tumors/21741428

الاتاحة: https://doi.org/10.1021/acs.jmedchem.2c01658.s002